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Abstract
Background: We developed multifactorial models for predicting incident dementia and brain pathology in the
oldest old using the Vantaa 85+ cohort.
Methods: We included participants without dementia at baseline and at least 2 years of follow-up (N = 245) for
dementia prediction or with autopsy data (N = 163) for pathology. A supervised machine learning method was
used for model development, considering sociodemographic, cognitive, clinical, vascular, and lifestyle factors, as
well as APOE genotype. Neuropathological assessments included β-amyloid, neurofibrillary tangles and neuritic
plaques, cerebral amyloid angiopathy (CAA), macro- and microscopic infarcts, α-synuclein pathology, hippocampal
sclerosis, and TDP-43.
Results: Prediction model performance was evaluated using AUC for 10 × 10-fold cross-validation. Overall AUCs
were 0.73 for dementia, 0.64–0.68 for Alzheimer’s disease (AD)- or amyloid-related pathologies, 0.72 for macroinfarcts,
and 0.61 for microinfarcts. Predictors for dementia were different from those in previous reports of younger
populations; for example, age, sex, and vascular and lifestyle factors were not predictive. Predictors for dementia versus
pathology were also different, because cognition and education predicted dementia but not AD- or amyloid-related
pathologies. APOE genotype was most consistently present across all models. APOE alleles had a different impact: ε4
did not predict dementia, but it did predict all AD- or amyloid-related pathologies; ε2 predicted dementia, but it was
protective against amyloid and neuropathological AD; and ε3ε3 was protective against dementia, neurofibrillary
tangles, and CAA. Very few other factors were predictive of pathology.
Conclusions: Differences between predictors for dementia in younger old versus oldest old populations, as well as for
dementia versus pathology, should be considered more carefully in future studies.
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Background
The oldest old constitute the largest and fastest growing
population with dementia [1], but they are less often the
focus of dementia prevention studies. Cohort studies
with participants aged 85+ years [2–7] have investigated
individual risk factors in association with dementia, but
the predictive value of more complex multifactorial risk
profiles in the oldest old is still unclear. Several dementia
risk scores have been developed in younger populations,
but they tend to perform poorly for predicting dementia
in the oldest old age groups [8, 9]. The association of
vascular and lifestyle-related factors with dementia risk,
for example, has been shown to vary with age [10], and
risk profiles predictive of subsequent dementia can differ
between midlife and older age [9].
While most multifactorial prediction models or risk
scores have focused on dementia, less is known about
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longitudinal prediction of neuropathology in people
without dementia. In the oldest old, multiple dementia-
related pathologies are common [11], but the association
with a dementia diagnosis may be less straightforward
than in younger age groups [10]. In this context, it be-
comes particularly important to investigate potential dif-
ferences between predictors for dementia and for
specific types of neuropathologies.
The main aims of the present study based on the Van-
taa 85+ cohort are to develop multifactorial models for
(1) predicting incident dementia in the oldest old, con-
sidering sociodemographic, cognitive, clinical, lifestyle,
and apolipoprotein E (APOE) genotype data; and (2) pre-
dicting dementia-related neuropathologies at death in
the oldest old, including Alzheimer’s disease (AD)-re-
lated pathology (amyloid plaques and neurofibrillary tan-
gles), cerebral amyloid angiopathy (CAA), cerebral
macro- and microinfarcts, and Lewy body pathology
(α-synuclein).
Methods
Study population
The Vantaa 85+ study has been described in detail previ-
ously [4, 12]. In brief, the study focused on residents in
the City of Vantaa in southern Finland who were at least
85 years old in 1991. Of the 601 people invited to par-
ticipate, 11 refused, 1 could not be reached, and 1 died,
leaving 588 (98%) participants who gave informed con-
sent to participate in the study. Additionally, 35 people
died before the baseline clinical examination, which was
done for 553 participants. At baseline, 214 participants
were diagnosed with dementia, and 339 did not have de-
mentia. Clinical reexaminations were conducted in 1994,
1996, 1999, and 2001. At the time of death, additionally
101 participants had been diagnosed with dementia.
Postmortem examination was conducted for 288 partici-
pants who attended the baseline clinical examination
and 16 who had died before baseline. The Vantaa 85+
study was approved by the ethics committee of the
Health Centre of the City of Vantaa. Written consent for
the autopsies was given by the nearest relatives of the
deceased.
To reduce the effects of mortality, of the 339 without
dementia at baseline, 94 participants who died within
the first 2 years of follow-up were excluded from the de-
mentia prediction model. This eliminated significant
time-to-death differences between individuals who died
with and without dementia. Of the 245 remaining partic-
ipants without baseline dementia and who were included
in the model development (Fig. 1), 97 subsequently de-
veloped dementia.
The study population used for neuropathological pre-
diction model development included 163 participants
who attended the baseline examination, did not have de-
mentia at baseline, and had available autopsy data. Par-
ticipants with baseline dementia were excluded to enable
comparison with the dementia prediction model.
Assessment of factors included in prediction models
Factors included in prediction models were assessed at
the baseline clinical evaluation, when participants were
examined by a physician and interviewed on their health,
health-related behavior, and medication by a trained
nurse. Medical history was additionally verified using
primary health care records. Sociodemographic factors
included age, sex, years of formal education, and social
Fig. 1 Study design flowchart
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class [13]. Cognition was assessed with the Mini Mental
State Examination (MMSE) [14] and the Short Portable
Mental Status Questionnaire (SPMSQ; recorded number
of errors) [15]. Participants self-reported subjective
memory decline on a scale of no/a little/yes. Functional
abilities were evaluated using activities of daily living
(ADL) and the Instrumental Activities of Daily Living
Scale (IADL) [16, 17]. Competence in daily activities was
also assessed in the interview with a single question with
six answer options ranging from “independent” (1 point)
to “needs help in all activities” (6 points). The Zung
Self-Rating Depression Scale was administered to assess
depressive symptoms [18]. Comorbidities included in
prediction models were diabetes, cardiovascular condi-
tions (angina pectoris, heart infarction, atrial fibrillation,
heart failure, arteriosclerosis obliterans, or hypertension)
and cerebrovascular conditions (stroke or transient is-
chemic attack). Other vascular and lifestyle-related fac-
tors were systolic and diastolic blood pressure, body
mass index (BMI), alcohol use, and smoking.
Total cholesterol as well as high-density lipoprotein
(HDL) and low-density lipoprotein (LDL) cholesterol
were quantified from baseline blood samples using en-
zymatic methods [4]. APOE genotyping was done with a
combination of DNA minisequencing [19] and DNA
amplification through PCR followed by restriction en-
zyme digestion with HhaI [20].
Dementia diagnosis
Dementia was diagnosed according to the revised cri-
teria of the Diagnostic and Statistical Manual of Mental
Disorders, Third Edition [21]. AD and vascular dementia
were diagnosed using the National Institute of Neuro-
logical and Communicative Disorders–Alzheimer’s Dis-
ease and Related Disorders Association [22] and
National Institute of Neurological Disorders and Stroke–
Association Internationale pour la Recherche en l’En-
seignement en Neurosciences [23] criteria. Diagnosis
was based on a broad range of information, including in-
terviews, health examinations, cognitive and functional
assessments, and health and social work records (e.g., in-
formation on home services or other social care services
provided to participants based on diminished functional
or cognitive capacity). Diagnoses were made by consen-
sus of two neurologists.
Incident dementia cases were identified from medical
and social work records, as well as from the informa-
tion collected at the study follow-up visits using exami-
nations and interviews with participants and their
relatives or caregivers [24]. Although clinicians were
not blinded to cognitive/functional assessments during
these visits (e.g., MMSE, SPMSQ, ADL, IADL), diagno-
ses relied primarily on overall clinical judgment based
on all available information.
Neuropathological assessment
Neuropathological assessments have been described in
detail previously [12, 24–28]. In brief, brains obtained at
autopsy were fixed in phosphate-buffered 4% formalde-
hyde for at least 2 weeks and examined independently of
clinical data. For AD-related pathology, the Consortium
to Establish a Registry for Alzheimer’s disease (CERAD)
protocol was followed [29]. Methenamine silver staining
was used for β-amyloid [30], and the modified
Bielschowsky method was used for neurofibrillary tan-
gles and neuritic plaques [31]. As described previously,
β-amyloid load was determined as the average fraction
of cortical area covered by methenamine silver-stained
plaques in four neocortical samples [12]. The average
number of neurofibrillary tangles was also determined in
the four samples [25]. The CERAD scores and Braak
stages were defined as originally described [29, 32]. CAA
was analyzed in six brain regions (frontal, parietal, tem-
poral and occipital lobes, hippocampus, and cerebellum)
based on Congo red staining and confirmed using IHC
against β-amyloid peptide [26]. Macroscopic infarcts
(cavitary lesions or solid cerebral infarcts visible to the
naked eye) were identified from sliced cerebral hemi-
spheres, brainstem, and cerebellum. All lesions were his-
tologically ascertained to be infarcts. Cortical
microinfarcts were analyzed in the H&E-stained tissue
sections in the same six brain regions as CAA [26]. They
were focal lesions smaller than 2 mm invisible to the
naked eye with neuronal loss, glial cell and macrophage
reaction, and/or cystic tissue necrosis. Sections of sub-
stantia nigra stained with the H&E method and sections
of substantia nigra and hippocampus stained with anti-
bodies against α-synuclein were used to screen for Lewy
body-related pathology [27].
Hippocampal sclerosis (HS) and TDP-43 (transactive
response binding protein 43) immunopositivity in the
granular cell layer of the hippocampus were assessed as
previously described [28]. In summary, HS and hemi-
spheric symmetry/asymmetry were determined on H&E
staining by estimating the severity of neuronal loss. The
density of neurons was assessed semiquantitatively by
three observers. For TDP-43 immunostaining, right-
sided hippocampus tissue blocks were cut into
4-μm-thick sections and stained with the Lab Vision
immunostainer (Thermo Fisher Scientific, Waltham,
MA, USA), and polymer-based kits were used for
detection.
Disease State Index
The Disease State Index (DSI) is a supervised machine
learning method designed for predicting disease out-
comes and differential diagnostics as a clinical
decision-making tool. A detailed description has been
published previously [33]. Compared with traditional
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methods for developing dementia risk scores, DSI is able
to deal with larger amounts of heterogeneous data, to
handle missing data, and to use unprocessed data with-
out prespecified cutoffs for predictors. Conceptually
related factors are structured into groups, such as com-
bining all cognitive tests. This is useful for filtering noise
and preventing strongly correlated factors from being
multiplied. DSI thus provides detailed information about
predictive performance on multiple levels simultan-
eously: the independent performance of each factor, the
combined performance of a group of similar factors, and
the overall performance of the entire model. DSI has
accuracy comparable to that of methods such as logistic
regression, support vector machines, and Bayes inference
[33] and has previously been used for predicting demen-
tia [34], progression of mild cognitive impairment [33,
35, 36], and differential diagnosis of neurodegenerative
diseases [37].
DSI builds a model from the distributions of data
using a population with known outcomes. For tested
individuals, DSI gives index values ranging from 0 to
1, describing similarity of the data to the distributions
in the model. A value close to 0 indicates that the data
are similar to controls (no subsequent dementia or
pathology), while a value close to 1 shows similarity to
cases (subsequent dementia or pathology). The data
used for the predictions can be dichotomous, continu-
ous, or categorical.
First, a fitness function is calculated for each factor.
Fitness function f(x) is the share of false-negative er-
rors divided by the sum of false-negative and
false-positive errors, using measurement value x as a
threshold for classification. It goes through the distri-
bution using each point as a classification threshold to
evaluate the shares of false-negatives and false-posi-
tives, assigning 0 to values unique to controls and 1 to
values unique to cases.
To complement fitness, a relevance value is calculated
for each measure. The relevance value ranges from 0 to
1 and indicates the ability, based on the data, to differen-
tiate between cases and controls in general. Relevance is
defined as the sum of sensitivity and specificity minus 1,
also known as the Youden index. Two data distributions
that are completely overlapping will receive a relevance
of 0, while two distributions with no overlap will get a
relevance of 1.
Conceptually related factors are structured into groups
to combine the effect of possibly correlating factors to a
single predictor. Individual factors are combined into a
group DSI value through a weighted average based on
their relevance values. This process is then repeated re-
cursively for all groups to obtain a total DSI value. Any
missing values are ignored as part of the model, and the
total score is calculated only from the available values.
Data analysis
We built DSI models for predicting dementia and the
different neuropathologies. AUCs with 95% CIs for a
10 × 10-fold cross-validation were calculated to evaluate
model performance. The dataset was divided into ten
random subgroups, where nine were combined to form
the training group and one acted as the test group. This
process was completed for each subgroup, and the
cross-validation itself was repeated ten times. Thus, we
show mean AUCs and 95% CIs resulting from the 10 ×
10 cross-validation process. Factor selection was con-
ducted before the model building; that is, only factors
that were significantly different (p < 0.05) between the
groups with and without the outcome of interest were
included in the final models. The initial list of factor
groups and individual factors included sociodemo-
graphics (age, sex, education, social class), cognition
(MMSE total score, MMSE orientation, MMSE word list
- sum of registration and recall tasks, MMSE calculation,
MMSE other tasks, and SPMSQ), functioning (sum of
ADL and IADL, competence in daily activities question,
and subjective memory decline), APOE genotype (binary
variables: ε2 carrier versus noncarrier, ε4 carrier versus
noncarrier, genotype ε3ε3 versus others; and a categor-
ical variable: all genotypes [ε2ε2, ε2ε3, ε2ε4, ε3ε3, ε3ε4,
or ε4ε4]), comorbidities (cardiovascular, cerebrovascular,
and diabetes), cholesterol (total, LDL, and HDL), blood
pressure (systolic and diastolic), lifestyle (BMI, alcohol
use, and smoking), and depressive symptoms (Zung
Self-Rating Depression Scale).
The following neuropathological outcomes were di-
chotomized as present versus absent: β-amyloid load
(average fraction of cortical area covered by methena-
mine silver-stained plaques > 0), tangle count (average
number of neurofibrillary tangles > 0), CAA (average
percentage of blood vessels with CAA > 0), cerebral
macroinfarcts (total number > 0), microinfarcts (num-
ber > 0), α-synuclein (brainstem, limbic, or diffuse neo-
cortical pathology present versus absent), HS (severe
marked/total loss versus no/minor loss of pyramidal
neurons in the CA1 and subiculum), and TDP-43
(immunopositivity in the granular cell layer present ver-
sus absent). Neuropathological AD was defined on the
basis of National Institute on Aging–Alzheimer’s Associ-
ation criteria [38] using the combination of Braak and
CERAD scores, and it was dichotomized as present
(intermediate or high likelihood of AD) versus absent
(low likelihood of AD).
To investigate relationships between neuropathological
variables and how they predict dementia, we con-
ducted principal component analysis (PCA) in 159 par-
ticipants without dementia at baseline and who had
complete neuropathological data. The pca function in
MATLAB R2015b (MathWorks, Natick, MA, USA) was
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used. The pathology variables were centered but not
weighted by variance. The principal component (PC)
scores of each participant were used as predictors for de-
mentia, and predictive performance for each PC was
assessed using AUC values.
Results
Predicting dementia
Characteristics for the dementia prediction population
are shown in Table 1. The population consisted of 245
participants without dementia at baseline who were
alive for at least 2 more years. Mean follow-up was 5.6
years, and 97 (40%) of the participants developed de-
mentia before death. Education, performance in MMSE,
SPMSQ, and competence in daily activities were signifi-
cantly lower in people with subsequent dementia. Dif-
ferences were also detected for APOE genotype. Other
baseline characteristics were not significantly different
between groups (Table 1) and were excluded from the
prediction model.
Cross-validation results for the DSI model for pre-
dicting dementia development are shown in Table 2.
AUC was 0.73 for the entire model. According to AUC
values for the groups of predictors, cognition including
SPMSQ and both MMSE total score and its four sub-
categories (orientation, calculation, word list, and other
tasks), were the most important predictors of dementia,
followed by functioning (competence in daily activities),
sociodemographics (education), and APOE status.
APOEε2 carrier status predicted dementia development
before death, while the ε3ε3 genotype was protective
against dementia development, although AUCs were
relatively low. The impact of APOEε2 and other major
predictors was similar in further analyses considering
clinical diagnosis of AD and vascular dementia separ-
ately (results not shown).
Predicting pathology
For predicting pathology, we included the 163 partici-
pants with no dementia at baseline and available autopsy
data. This population had a mean age of 88.7 years, a
follow-up time of 4.1 years, and 4.3 years of education.
Thirty-one (19%) of these participants were male, 33
(21%) of them were APOEε4 carriers, and 26 (17%) were
ε2 carriers. Fifty-nine (36%) had dementia at death.
Cross-validation results (AUCs) of the DSI pathology
prediction models are shown in Table 3. Sensitivities and
specificities are shown in Additional file 1: Table S1. The
total AUCs for AD- or amyloid-related pathologies were
0.66 for amyloid load, 0.64 for tangle count, 0.68 for
neuropathological AD, and 0.66 for CAA. APOE geno-
type had the highest AUCs for all these pathologies, but
there were differences in the impact of different alleles.
APOEε4 carrier status was predictive for all four
pathology outcomes, while APOEε2 carrier status was
protective against β-amyloid load and neuropathological
AD. The ε3ε3 genotype was protective against tangle
count and CAA, but it was not related to amyloid load
or neuropathological AD.
Very few other factors had predictive value (Table 3):
poorer competence in daily activities for β-amyloid load,
higher total and LDL cholesterol, and subjective memory
decline for tangle count; lower social class and subjective
memory decline for neuropathological AD; and absence
of cardiovascular comorbidity and male sex for CAA.
The model for cerebral macroinfarcts had the best
predictive performance with total AUC of 0.72 (Table 3).
The predictors in descending order of AUC values were
history of cerebrovascular conditions, poorer MMSE
score (total and word list learning and recall tasks),
higher BMI, and poorer competence in daily activities.
We also modeled the two most common subtypes of
cerebral macroinfarcts: cortical and white matter. Cortical
macroinfarcts (AUC of 0.71) were predicted by cerebro-
vascular comorbidity and APOE genotype. APOEε4 car-
riers were more likely to develop cortical macroinfarcts,
while genotype ε3ε3 was protective. White matter macro-
infarcts (AUC of 0.76) were predicted by cholesterol, cere-
brovascular comorbidity, and APOEε2 carrier status. The
AUC for the cerebral microinfarcts model was 0.61, with
education as the only predictor.
HS (AUC of 0.78) was predicted by cognition (MMSE
total score, word list learning and recall, and other
tasks). Current smokers were also more likely to have
HS (Table 3). TDP-43 was only predicted by less pro-
nounced depressive symptoms (AUC of 0.69). There
were no significant predictors found for α-synuclein.
Overall, APOE genotype was the predictor that emerged
most consistently across all models. The impact of APOE
on dementia versus pathology is summarized in Fig. 2.
Associations between pathology and dementia at death
in participants without dementia at baseline are shown in
Additional file 1: Table S2, and results of the PCA analysis
are provided in Additional file 1: Table S3. The first three
components of PCA explained 56% of the variance in aut-
opsy findings and reflected three mostly independent
pathological processes: AD-/amyloid-related pathology,
including β-amyloid, neurofibrillary tangles, and CAA
(PC1); vascular-type pathology, including primarily
macroscopic infarcts (PC2); and Lewy body-type path-
ology, including α-synuclein (PC3). PC1 was most predict-
ive of dementia (AUC of 0.71), followed by PC2
(AUC of 0.60). The other PCs did not predict dementia.
Discussion
Predicting dementia in the oldest old
The DSI model performance for predicting dementia on-
set before death, on average 6 years later, in people aged
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Table 1 Baseline characteristics of the dementia prediction population
Characteristics No dementia at death (n = 148) Dementia at death (n = 97) p Value
Follow-up time, years 5.4 (2.7) 5.8 (2.6) 0.3
Sociodemographics
Age at baseline, years 88.4 (2.6) 88.3 (2.6) 0.7
Men, n (%) 33 (22%) 19 (20%) 0.6
Education, years 4.6 (3.3) 3.7 (2.0) 0.01
Social class 6.0 (1.5) 6.2 (1.3) 0.2
Cognition
MMSE Total 25.3 (3.3) 22.2 (4.5) < 0.001
MMSE Calculation 3.4 (1.6) 2.9 (1.6) 0.02
MMSE Orientation 9.5 (0.8) 8.7 (1.6) < 0.001
MMSE Other tasks 7.4 (1.2) 6.7 (1.4) < 0.001
MMSE Wordlist 5.0 (1.1) 4.2 (1.3) < 0.001
SPMSQ 0.8 (1.4) 1.8 (1.9) < 0.001
Functioning
Competence in daily activities 2.6 (1.3) 3.2 (1.4) 0.001
ADL sum (ADL + IADL) 29.7 (10.2) 31.6 (10.1) 0.2
Subjective memory decline 1.7 (0.6) 1.9 (0.7) 0.05
APOE genotype
ε2ε3 17 (12%) 18 (19%) 0.02
ε2ε4 1 (1%) 5 (6%)
ε3ε3 101 (69%) 53 (55%)
ε3ε4 27 (18%) 18 (19%)
ε4ε4 0 (0%) 1 (1%)
Comorbidity, n (%)
Cardiovascular 114 (77%) 66 (68%) 0.1
Cerebrovascular 22(15%) 19 (20%) 0.3
Diabetes 29 (20%) 28 (29%) 0.09
Cholesterol, mmol/L
Total cholesterol 5.9 (1.3) 5.7 (1.1) 0.2
LDL cholesterol 4.0 (1.2) 3.8 (1.0) 0.2
HDL cholesterol 1.0 (0.3) 1.1 (0.3) 0.2
Blood pressure, mmHg
Systolic 161 (25) 157 (27) 0.2
Diastolic 85 (11) 84 (12) 0.6
Lifestyle factors
BMI 25.4 (4.4) 24.9 (3.6) 0.3
No alcohol use, n (%) 99 (67%) 67 (69%) 0.8
Nonsmokers, n (%) 144 (97%) 95 (98%) 0.7
Depressive symptoms
Zung Self-Rating Depression Scale 26.8 (5.8) 26.7 (5.5) 1
Abbreviations: ADL Activities of daily living, APOE Apolipoprotein E, BMI body mass index, HDL/LDL High-/low-density lipoprotein, IADL Instrumental activities of
daily living, MMSE Mini Mental State Examination, SPMSQ Short Portable Mental Status Questionnaire
Values are shown as mean (SD) or number (percent). p Values were calculated with the Mann-Whitney U test or χ2 test for categorical variables. Social class is
categorized on a scale from 1 (lowest) to 10 (highest) [13]
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85+ years was close to the 10-year DSI dementia predic-
tion model in a younger-old population [34] and was in
the upper range of reported performance for previous
dementia risk scores in younger populations [9]. Simi-
larly to other dementia risk scores [9, 34], cognition was
the main predictor, followed by functioning and educa-
tion levels. However, there were several important differ-
ences compared with younger populations. Age, sex, and
vascular and lifestyle factors were not predictive of de-
mentia in the present study, although they are usually
important predictors in midlife. The age range for 85+
populations is inherently smaller than for younger co-
horts, potentially limiting the predictive value of age. In-
dividuals who survive to the age of 85 years without
dementia are also a selected group. While mechanisms
are not fully clear, associations of vascular and lifestyle
factors with dementia have been reported to differ in
midlife versus late life [10].
APOE genotype was related to incident dementia, but
the pattern was different from that in younger popula-
tions, where the ε4 allele increases dementia risk, while
the ε2 allele seems protective (www.alzgene.org). In the
present study, APOEε4 carrier status was not important
for dementia prediction, in line with previous findings in
the oldest old [39, 40]. The ε3ε3 genotype was protect-
ive, while the ε2 allele was predictive of subsequent de-
mentia. Compared with younger populations, a lower
proportion of ε4 carriers and a higher proportion of ε2
carriers have been reported in the oldest old [10, 40], in-
cluding the Vantaa 85+ cohort [41]. Three previous
population-based studies with shorter follow-up than
Vantaa 85+ reported no protective effect of the ε2 allele
against incident dementia after the age of 85 years [40,
42, 43]. Additionally, the ε2 allele increased the risk of
incident vascular dementia in one study [42]. Previous
reports on lower risk of dementia among the oldest old
APOEε2 carriers have come from cross-sectional studies
of dementia prevalence at death [44], and this may not
necessarily apply longitudinally to dementia incidence
after the age of 85 years.
Predicting dementia versus predicting neuropathology
The APOE genotype consistently predicted AD- or
amyloid-related pathologies at death on average 6 years
later, but with a different pattern than for incident de-
mentia. The ε4 allele predicted all these pathologies.
ε3ε3 genotype was protective against neurofibrillary tan-
gles and CAA. The ε2 allele was protective against
β-amyloid load and neuropathological AD. This pattern
is closer to findings derived from younger-old popula-
tions, where the ε4 allele increases the risk and ε2 allele
decreases the risk of subsequent AD-related pathology
[45]. A conflicting finding was reported in the 90+
Study, where ε2 carriers had increased CERAD scores in
Table 2 Dementia prediction model
Predictors AUC [95% CI] Sensitivity [95% CI] Specificity [95% CI]
Entire modela 0.73 [0.68–0.78] 0.66 [0.63–0.69] 0.68 [0.66–0.71]
Cognitionb 0.72 [0.66–0.78] 0.55 [0.51–0.59] 0.55 [0.52–0.58]
MMSE Calculationc 0.60 [0.53–0.68] 0.53 [0.49–0.56] 0.68 [0.66–0.70]
MMSE Orientationc 0.64 [0.58–0.70] 0.68 [0.65–0.71] 0.54 [0.51–0.56]
MMSE Other tasksc 0.65 [0.58–0.72] 0.56 [0.53–0.58] 0.67 [0.65–0.69]
MMSE Wordlistc 0.68 [0.62–0.75] 0.77 [0.75–0.80] 0.57 [0.55–0.60]
SPMSQc 0.71 [0.65–0.77] 0.67 [0.65–0.70] 0.64 [0.62–0.67]
MMSE totalc 0.71 [0.64–0.77] 0.62 [0.59–0.65] 0.61 [0.58–0.63]
Functioningb 0.61 [0.55–0.67] 0.62 [0.59–0.65] 0.61 [0.58–0.63]
Competence in daily activitiesc 0.61 [0.55–0.67] 0.83 [0.81–0.86] 0.35 [0.32–0.38]
Sociodemographicsb 0.60 [0.54–0.65] 0.83 [0.81–0.86] 0.35 [0.32–0.38]
Education, yearsc 0.60 [0.54–0.65] 0.66 [0.63–0.69] 0.68 [0.66–0.71]
APOE genotypeb 0.58 [0.52–0.64] 0.45 [0.42–0.47] 0.69 [0.67–0.71]
APOEε2 carriersc 0.56 [0.51–0.61] 0.25 [0.23–0.27] 0.88 [0.86–0.89]
APOEε3ε3 genotypec 0.57 [0.51–0.63] 0.45 [0.42–0.47] 0.69 [0.67–0.71]
All genotypesc,d (23/24/33/34/44) 0.58 [0.51–0.64] 0.67 [0.64–0.70] 0.66 [0.63–0.68]
Abbreviations: APOE Apoliprotein E, MMSE Mini Mental State Examination, SPMSQ Short Portable Mental Status Questionnaire
AUC, sensitivity and specificity [95% CI] values using the cutoff point Disease State Index (DSI) = 0.5 are shown for 10 × 10-fold cross-validation of the DSI model.
Numbers of participants with missing data were 3 for education and 3 for APOE genotype
aOverall model performance
bOverall performance of each group of related predictors
cPerformance of each individual predictor
dCategorical variable including genotype ε2ε3, ε2ε4, ε3ε3, ε3ε4, or ε4ε4
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Table 3 Neuropathology prediction models
Neuropathological
outcomes
Predictors AUC [95%CI] Description of predictors by neuropathological outcome
categories
Absent Present
β-Amyloid load Overall modela 0.66 [0.56 - 0.77] N=37 (23%) N=126 (77%)
APOE genotypeb 0.63 [0.56 - 0.71]
APOEε2 carriersc 0.57 [0.50 - 0.64] 10 (27%) 16 (13%)
APOEε4 carriersc 0.60 [0.55 - 0.65] 2 (5%) 31 (25%)
All genotypes (23/24/33/34/44)c,d 0.62 [0.54 - 0.70] 9/1/26/1/0
(24/3/70/3/0%)
13/3/78/28/0
(11/2/64/23/0%)
Functioningb 0.61 [0.51 - 0.70]
Competence in Daily Activitiesc 0.61 [0.51 - 0.70] 2.7 (1.4) 3.2 (1.4)
Tangle count Overall modela 0.64 [0.55 - 0.73] N=64 (39%) N=99 (61%)
APOE genotypeb 0.60 [0.54 - 0.67]
APOEε4 carriersc 0.61 [0.55 - 0.67] 5 (8%) 28 (29%)
APOE ε3ε3 genotypec 0.59 [0.52 - 0.66] 48 (75%) 56 (58%)
All genotypes (23/24/33/34/44)c,d 0.55 [0.48 - 0.62] 10/1/48/4/0
(16/2/76/6/0%)
12/3/56/25/0
(13/3/58/26/0%)
Cholesterolb 0.60 [0.51 - 0.70]
Totalc 0.61 [0.51 - 0.70] 5.6 (1.4) 5.9 (1.2)
LDLc 0.60 [0.50 - 0.69] 3.6 (1.1) 3.9 (1.0)
Functioningb 0.59 [0.50 - 0.67]
Subjective memory declinec 0.59 [0.50 - 0.67] 1.7 (0.6) 1.9 (0.7)
Neuropathological AD Overall modela 0.68 [0.61 - 0.76] N=86 (53%) N=77 (47%)
APOE genotypeb 0.65 [0.59 - 0.71]
APOEε2 carriersc 0.57 [0.51 - 0.62] 19 (23%) 7 (9%)
APOEε4 carriersc 0.62 [0.57 - 0.67] 8 (10%) 25 (33%)
All genotypes (23/24/33/34/44)c,d 0.64 [0.58 - 0.70] 17/2/59/6/0
(20/2/70/7/0%)
5/2/45/23/0
(7/3/60/31/0%)
Sociodemographicsb 0.62 [0.53 - 0.70]
Social classc 0.62 [0.53 - 0.70] 6.4 (1.5) 5.9 (1.2)
Functioningb 0.58 [0.50 - 0.66]
Subjective memory declinec 0.58 [0.50 - 0.66] 1.7 (0.6) 1.9 (0.7)
Cerebral amyloid angiopathy Overall modela 0.66 [0.58 - 0.74] N=56 (35%) N=103 (65%)
APOE genotypeb 0.62 [0.55 - 0.69]
APOEε4 carriersc 0.63 [0.58 - 0.68] 2 (4%) 30 (30%)
APOE ε3ε3 genotypec 0.59 [0.52 - 0.67] 43 (78%) 59 (59%)
All genotypes (23/24/33/34/44)c,d 0.61 [0.55 - 0.68] 10/1/43/1/0
(18/2/78/2/0%)
11/3/59/27/0
(11/3/59/27/0%)
Comorbidityb 0.59 [0.52 - 0.65]
Cardiovascularc 0.59 [0.52 - 0.65] 48 (86%) 70 (68%)
Sociodemographics 0.58 [0.53 - 0.64]
Gender, menc 0.58 [0.53 - 0.64] 5 (9%) 26 (25%)
Cerebral macroinfarcts Overall modela 0.72 [0.64 - 0.79] N=83 (51%) N=80 (49%)
Comorbidityb 0.64 [0.58 - 0.70]
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Table 3 Neuropathology prediction models (Continued)
Neuropathological
outcomes
Predictors AUC [95%CI] Description of predictors by neuropathological outcome
categories
Absent Present
Cerebrovascularc 0.64 [0.58 - 0.70] 4 (5%) 26 (33%)
Cognitionb 0.63 [0.54 - 0.72]
MMSE Wordlistc 0.63 [0.55 - 0.71] 4.6 (1.3) 4.0 (1.3)
MMSE Totalc 0.62 [0.52 - 0.71] 23.8 (4.6) 22.0 (4.5)
Lifestyleb 0.62 [0.53 - 0.70]
BMIc 0.62 [0.53 - 0.70] 23.9 (4.1) 25.5 (4.2)
Functioningb 0.59 [0.51 - 0.66]
Competence in Daily Activitiesc 0.59 [0.51 - 0.66] 2.9 (1.4) 3.3 (1.3)
Cortical macroinfarcts Overall modela 0.71 [0.63 - 0.79] N=116 (71%) N=47 (29%)
Comorbidityb 0.64 [0.57 - 0.71]
Cerebrovascularc 0.64 [0.57 - 0.71] 12 (10%) 18 (38%)
APOE genotypeb 0.60 [0.51 - 0.69]
APOEε4 carriersc 0.58 [0.51 - 0.65] 18 (16%) 15 (33%)
APOE ε3ε3 genotypec 0.59 [0.50 - 0.68] 80 (71%) 24 (52%)
White matter macroinfarcts Overall modela 0.76 [0.65 - 0.87] N=140 (86%) N=23 (14%)
Cholesterolb 0.72 [0.60 - 0.83]
HDLc 0.68 [0.58 - 0.79] 1.0 (0.3) 0.9 (0.3)
LDLc 0.70 [0.58 - 0.83] 3.9 (1.0) 3.2 (1.0)
Comorbidityb 0.62 [0.51 - 0.73]
Cerebrovascularc 0.62 [0.51 - 0.73] 21 (15%) 9 (39%)
APOE genotypeb 0.61 [0.50 - 0.71]
APOEε2 carriersc 0.61 [0.50 - 0.71] 18 (13%) 8 (35%)
Cerebral microinfarcts Overall modela 0.61 [0.51 - 0.71] N=130 (83%) N=26 (17%)
Education yearsc 0.61 [0.51 - 0.71] 4.5 (2.9) 3.3 (1.8)
Hippocampal Sclerosis Overall modela 0.78 [0.64 - 0.91] N=151 (93%) N=11 (7%)
Cognitionb 0.75 [0.59 - 0.92]
MMSE Wordlistc 0.68 [0.54 - 0.83] 4.4 (1.3) 3.6 (0.9)
MMSE Other tasksc 0.74 [0.57 - 0.90] 6.9 (1.5) 5.8 (1.4)
MMSE Totalc 0.72 [0.55 - 0.90] 23.1 (4.6) 22.3 (4.1)
Lifestyleb 0.57 [0.42 - 0.71]
Current smokingc 0.57 [0.42 - 0.71] 4 (3%) 2 (18%)
TDP-43 Overall modela 0.69 [0.56 - 0.81] N=139 (86%) N=21 (13%)
Zung depression scalec 0.69 [0.56 - 0.81] 27.5 (5.8) 23.7 (2.8)
Abbreviations: AD Alzheimer’s Disease, APOE Apolipoprotein E, BMI body mass index, HDL/LDL High/low density lipoprotein, MMSE Mini-Mental State Examination,
SPMSQ Short portable mental status questionnaire, TDP-43 TAR DNA-binding protein 43.
AUC [95% CI] values are shown for 10*10-fold cross-validation of the DSI model. In the “Description of predictors…” columns, values are shown as mean (standard
deviation) or number (percentage). Number of participants with missing data was 4 for cerebral amyloid angiopathy, 4 for cerebral microinfarcts, , 4 for APOE
genotype, 5 for MMSE, 6 for subjective memory, 3 for education, 1 for social class, 1 for smoking, 3 for Zung scale, 10 for cholesterol, and 39 for BMI.
aOverall model performance for each neuropathological outcome
bOverall performance of each group of related predictors.
cPerformance of each individual predictor
dCategorical variable including genotype ε2ε3, ε2ε4, ε3ε3, ε3ε4 or ε4ε4
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cross-sectional analyses at death [44]. However, further
analyses showed lower cortical β-amyloid percentage
areas in ε2 carriers [46].
While APOE was not related to cerebral macroinfarcts
in general in the present study, the ε4 allele predicted
cortical macroinfarcts, and the ε2 allele predicted white
matter macroinfarcts. A meta-analysis of studies in
younger populations has linked both the ε4 and ε2 al-
leles to increasing burden in magnetic resonance im-
aging markers of cerebrovascular disease, including
white matter hyperintensities [47]. However, longitudinal
associations of APOE genotype with subsequent cerebro-
vascular lesions in the oldest old are still unclear. In the
Vantaa 85+ study, while white matter infarcts alone were
not significantly related to dementia diagnosis at death,
they may suggest a potential explanation for the predict-
ive effect of APOEε2 on incident dementia.
Very few other factors besides APOE predicted neuro-
pathology. Vascular and lifestyle factors did not predict
β-amyloid load or neuropathological AD. It is still de-
bated whether vascular and lifestyle risk factors for de-
mentia are actually related to amyloid pathology and
whether such relationships may be age-dependent. Our
finding that higher LDL and total cholesterol predicted
tangle count needs to be verified in other 85+ cohorts.
Cognitive performance was not predictive of AD- or
amyloid-related pathologies, although it predicted de-
mentia, cerebral macroinfarcts, and HS. Of the included
sociodemographic factors, only lower social class pre-
dicted neuropathological AD.
Predictors for HS and TDP-43 pathology are still un-
clear. While current smoking was related to HS and less
pronounced depressive symptoms were related to TDP-
43, the number of participants with these pathologies
was very small in this study, and these findings require
verification in other cohorts.
Overall, predictive performance of the models (AUC,
sensitivity, specificity) was not very high. While
study-specific limitations may have contributed to this,
it is also possible that neither incident dementia nor spe-
cific neuropathologies can be predicted with very high
accuracy in the oldest old using predictors commonly
emphasized in younger-old populations. This is also sug-
gested by the failure of previous dementia risk scores
when extrapolated from younger-old to oldest-old popu-
lations. Different approaches may be needed that better
account for the heterogeneity and multipathology often
existing within the 85+ age group.
Strengths and limitations of the present study
The main strength of the present study is the prospect-
ive population-based design with a high autopsy rate
over 10 years, the inclusion of participants aged > 85
years, and the multicomponent longitudinal prediction
models for both dementia and specific neuropathologies.
However, the developed prediction models are applicable
only to a highly selected group of individuals who sur-
vive to the age of 85 years without developing dementia.
External validation in other oldest-old cohorts will also
be needed. The Vantaa 85+ population may differ from
populations that are currently 85+ years old (e.g., for
relatively low education). Health-related measures prior
to the age of 85 years were not available. Sample size
may have limited statistical power, especially for patho-
logical outcomes with smaller numbers of participants.
Participants with autopsy were more likely to have in-
cident dementia and lower MMSE at baseline than those
without autopsy, which may have affected the pathology
Outcomes
APOE genotype
Dementia
AD/amyloid-
related pathology
-Amyloid load
Tangle count
Neuropathological AD
Cerebral amyloid angiopathy
Macroinfarcts
All
Cortical
White matter
Microinfarcts
Hippocampal sclerosis
TDP-43
4 2 3 3
Fig. 2 Impact of apolipoprotein E (APOE) genotype on dementia versus neuropathology. Red indicates alleles that predicted dementia/pathology.
Blue indicates alleles that were protective against dementia/pathology. White indicates alleles with no significant impact
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models. Participants with dementia at baseline were ex-
cluded from pathology models, but owing to their old
age, some pathology may have been present at baseline.
Quantitative, systematic methods were used for neuro-
pathological assessments, but findings based on trad-
itional silver-staining methods may be somewhat
different from IHC methods for AD pathology. Other
pathologies, such as aging-related tau astrogliopathy,
could not be included owing to lack of data.
Conclusions
This is the first study combining longer-term dementia
and neuropathology multicomponent prediction models
among the oldest old. The dementia risk profile in this
age group was very different from risk profiles previously
described at younger ages. Predictors of dementia did
not necessarily predict pathology. APOE genotype was
the most consistent predictor across all models, but with
different impact for different alleles.
The predictive models in the present study were devel-
oped for early identification of individuals with elevated
risk of subsequent dementia. Longitudinal prediction
models in the oldest old are more complex than in
younger-old populations, and multifactorial risk profiles
including both genetic and nongenetic factors need to
be further investigated.
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